PDE1A

Across TCGA pan-cancer cohorts, PDE1A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDE1A data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PDE1A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PDE1A expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where PDE1A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.870	0.350	.002	37	view →
LUAD	DFS	Median	III,IV	0.283	0.996	.038	6	view →
LSCC	DFS	Tertile	All	0.856	0.228	.024	3	view →
GBM	DFS	Quartile	All	0.846	0.619	.017	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDE1A–PDAC (DFS)

Open the PDAC breakdown →